Is Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-? Is Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- safe for nursing mother and child? Does Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- extracts into breast milk? Does Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- has any long term or short term side effects on infants? Can Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- influence milk supply or can Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- decrease milk supply in lactating mothers?

It is excreted in breast milk in clinically non-significant amount and no problems have been observed in infants whose mothers were receiving this treatment.Plasma levels in these infants were undetectable or very low. Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- may induce to an increase of plasma Prolactin levels. American Academy of Pediatrics: usually compatible with breastfeeding medication.WHO List of Essential Medicines 2002: compatible with breastfeeding.

Limited information indicates that maternal doses of Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- up to 360 mg daily produce low levels in milk and newborns may have detectable Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- serum levels, but levels are low. Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months.

No adverse reactions have been reported among 3 infants aged 13 days, 8 weeks and 3 months who were exposed to Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- in breastmilk.[2][3][4]

Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- can cause hyperprolactinemia and galactorrhea.[5][6] The clinical relevance of these findings in nursing mothers is not known. The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed.